These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 35743140)

  • 1. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2.
    Miura K; Yang L; van Rooijen N; Ohnishi H; Seki E
    Am J Physiol Gastrointest Liver Physiol; 2012 Jun; 302(11):G1310-21. PubMed ID: 22442158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.
    Parker R; Weston CJ; Miao Z; Corbett C; Armstrong MJ; Ertl L; Ebsworth K; Walters MJ; Baumart T; Newland D; McMahon J; Zhang P; Singh R; Campbell J; Newsome PN; Charo I; Schall TJ; Adams DH
    Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G483-G493. PubMed ID: 29420066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
    Fisher FM; Chui PC; Nasser IA; Popov Y; Cunniff JC; Lundasen T; Kharitonenkov A; Schuppan D; Flier JS; Maratos-Flier E
    Gastroenterology; 2014 Nov; 147(5):1073-83.e6. PubMed ID: 25083607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
    Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
    Lefere S; Devisscher L; Tacke F
    Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
    Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
    Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
    Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression.
    Kim HY; Yoo YH
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
    Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
    PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.
    Thapaliya S; Wree A; Povero D; Inzaugarat ME; Berk M; Dixon L; Papouchado BG; Feldstein AE
    Dig Dis Sci; 2014 Jun; 59(6):1197-206. PubMed ID: 24795036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artemisia argyi ethanol extract ameliorates nonalcoholic steatohepatitis-induced liver fibrosis by modulating gut microbiota and hepatic signaling.
    Erdenebileg S; Kim M; Nam Y; Cha KH; Le TT; Jung SH; Nho CW
    J Ethnopharmacol; 2024 Oct; 333():118415. PubMed ID: 38848971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
    Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
    Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.